Intermittent chemotherapy in metastatic androgen-independent prostate cancer

被引：44

作者：

Beer, TM

Garzotto, M

Henner, WD

Eilers, KM

Wersinger, EM

机构：

[1] Oregon Hlth Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA

[2] Portland VA Med Ctr, Div Urol, Portland, OR 97207 USA

来源：

BRITISH JOURNAL OF CANCER | 2003年 / 89卷 / 06期

关键词：

docetaxel; calcitriol; vitamin D; prostate cancer; chemotherapy;

D O I：

10.1038/sj.bjc.6601232

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Intermittent use of chemotherapy for androgen-independent prostate cancer ( AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml(-1). Chemotherapy was suspended until a rise in PSA ≥50% and 1 ng ml(-1). The median duration of treatment holiday was 20 weeks (13 - 43+ weeks) and all patients retained sensitivity to re-treatment. Chemotherapy holiday was associated with an improvement of fatigue ( P = 0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.

引用

收藏

页码：968 / 970

页数：3

相关论文

共 12 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2] Weekly high-dose calcitriol and docetaxel in advanced prostate cancer [J].

Beer, TM ;

Hough, KM ;

Garzotto, M ;

Lowe, BA ;

Henner, WD .

SEMINARS IN ONCOLOGY, 2001, 28 (04) :49-55

[3] Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group [J].

Bubley, GJ ;

Carducci, M ;

Dahut, W ;

Dawson, N ;

Daliani, D ;

Eisenberger, M ;

Figg, WD ;

Freidlin, B ;

Halabi, S ;

Hudes, G ;

Hussain, M ;

Kaplan, R ;

Myers, C ;

Oh, W ;

Petrylak, DP ;

Reed, E ;

Roth, B ;

Sartor, O ;

Scher, H ;

Simons, J ;

Sinibaldi, V ;

Small, EJ ;

Smith, MR ;

Trump, DL ;

Vollmer, R ;

Wilding, G .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3461-3467

[4] Chemotherapy for prostate cancer [J].

Gilligan, T ;

Kantoff, PW .

UROLOGY, 2002, 60 (3A) :94-100

[5]

GOLDENBERG SL, 1995, UROLOGY, V45, P839

[6] Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study [J].

Higano, CS ;

Ellis, W ;

Russell, K ;

Lange, PH .

UROLOGY, 1996, 48 (05) :800-804

[7] Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study [J].

Kantoff, PW ;

Halabi, S ;

Conaway, M ;

Picus, J ;

Kirshner, J ;

Hars, V ;

Trump, D ;

Winer, EP ;

Vogelzang, NJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2506-2513

[8] Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone [J].

Osoba, D ;

Tannock, IF ;

Ernst, DS ;

Neville, AJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1654-1663

[9] Interpreting the significance of changes in health-related quality-of-life scores [J].

Osoba, D ;

Rodrigues, G ;

Myles, J ;

Zee, B ;

Pater, J .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :139-144

[10] PSYCHOMETRIC PROPERTIES AND RESPONSIVENESS OF THE EORTC QUALITY-OF-LIFE QUESTIONNAIRE (QLQ-C30) IN PATIENTS WITH BREAST, OVARIAN AND LUNG-CANCER [J].

OSOBA, D ;

ZEE, B ;

PATER, J ;

WARR, D ;

KAIZER, L ;

LATREILLE, J .

QUALITY OF LIFE RESEARCH, 1994, 3 (05) :353-364